Company Overview and News

 
United Breweries Limited - News Clarification

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UBL UBHOLDINGS 507458 UNBWY 532478

 
Broker's Call: Coal India (buy)

2018-10-12 thehindubusinessline
While eco mine tourism is a novel concept in India, other countries have been harnessing its potential for a while now - REUTERS
UBL UBHOLDINGS 507458 CLNDY 533278 COALINDIA UNBWY 532478

 
Excise duty on jet fuel drives airline stocks up 6%

2018-10-12 thehindubusinessline
Airline stocks continued to gain for the third consecutive session on Friday, gaining up to 6 per cent, due to excise duty cut on jet fuel and easing crude prices. Shares of InterGlobe Aviation zoomed 6.03 per cent, Jet Airways rose 4.89 per cent and SpiceJet gained 3.63 per cent on the BSE.
INDIGO UBL 532617 UBHOLDINGS JETAIRWAYS 507458 UNBWY 539448 532478

 
Investor wealth soars Rs 2.98 lakh cr as stocks rally

2018-10-12 thehindubusinessline
As many as 29 stocks in the 30-share Sensex basket closed with gains. File Photo - BusinessLine
KMBKY UBL KOTAKBANK UBHOLDINGS 500247 507458 UNBWY 532478

 
United Breweries Limited - Updates

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UBL UBHOLDINGS 507458 UNBWY 532478

 
YES Bank shares gain nearly 3%

2018-10-12 thehindubusinessline
YES Bank gained nearly 3 per cent as the lender has appointed US-based headhunter Korn Ferry to assist an expert panel searching for a successor to the outgoing MD and CEO, Rana Kapoor.
YESBANK UBL UBHOLDINGS 532648 YYBKY 507458 UNBWY 532478

 
United Breweries Limited - News Clarification

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UBL UBHOLDINGS 507458 UNBWY 532478

 
Bandhan Bank gets SEBI exemption for 1-year promoter share lock-in

2018-10-12 thehindubusinessline
The exemption would help the bank comply with the Reserve Bank of India’s licensing norms which requires promoter holding to be brought down to 40 per cent within three years of starting operations.
UBL UBHOLDINGS 507458 UNBWY 532478

 
SEBI to auction properties of 4 companies

2018-10-12 thehindubusinessline
New Delhi, October 12 The Securities and Exchange Board of India will auction as many as six properties of four companies, including Swar Agrotech and Life Care Infratech, next month at a reserve price of Rs 5 crore. Properties of Servehit Housing and Infrastructure India and Raghav Capital and Infrastructure will also go under the hammer.
INFQF UBL UBHOLDINGS 507458 UNBWY IIP 532478

2
Shares in United Breweries slide following antitrust raids

2018-10-12 moneycontrol
Shares in India's United Breweries fell as much as 3 percent on Friday, a day after Reuters reported the brewer and two of its global rivals, had been raided in India as part of an ongoing investigation into price-fixing allegations.
BUD ABI UBL UBHOLDINGS AHBIF 507458 UNBWY 532478

 
Maruti Suzuki revs up 4 per cent

2018-10-12 thehindubusinessline
Maruti Suzuki India Ltd gained as much as 4.15 per cent and was quoted at Rs 7,158 today. The stock breached above the key resistance level at Rs 7,138.15. This level is identified as the 14.6 per cent Fibonacci retracement of the downtrend from July 24 high to Oct. 9 low. The stock touched an intraday high of Rs 7,199 today on the NSE.
MARUTI UBL UBHOLDINGS 507458 UNBWY MRZUY 532478 532500

 
Infy, Hero MotoCorp results on Oct 16

2018-10-12 thehindubusinessline
Shares of United Breweries Ltd fell as much as 3 per cent on Friday, a day ...
500182 UBL UBHOLDINGS HEROMOTOCO HRTQY 507458 UNBWY 532478

2
UB shares slide after competition watchdog raids

2018-10-12 thehindubusinessline
Shares of United Breweries Ltd fell as much as 3 per cent on Friday, a day after Reuters reported the brewer and two of its global rivals, had been raided in India as part of an ongoing investigation into price-fixing allegations.
BUD ABI UBL UBHOLDINGS AHBIF 507458 UNBWY 532478

2
United Breweries, AB Inbev, Carlsberg offices raided in price cartel probe

2018-10-12 thehindubusinessline
Antitrust watchdog raided the offices of three top beer companies on Thursday as part of an investigation of price-fixing allegations, three sources with direct knowledge of the matter told Reuters.
BUD ABI UBL UBHOLDINGS AHBIF 507458 UNBWY 532478

2
Top brewers raided by Indian watchdog in price-fixing probe — sources

2018-10-12 theedgemarkets
MUMBAI (Oct 12): India's antitrust watchdog raided the offices of three top beer companies on Thursday as part of an investigation of price-fixing allegations, three sources with direct knowledge of the matter told Reuters.
BUD ABI UBL UBHOLDINGS AHBIF 507458 UNBWY 532478

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...